AM-Pharma closes €7M round

Funding round completed

AM-Pharma BV has sealed a €7 million investment from with Forbion Capital Partners and Inventages Venture Capital in the first close of a third round funding in which the company aims to raise €20 million. The Dutch company is in discussions with several potential investors from both Europe and the US on the investment of another €13 million.

The company specialises in taking naturally occurring human proteins and improving their properties. The new money will allow it to generate further Phase II efficacy and safety data for its two products, Recombinant human Alkaline Phosphatase and Selective Immune Response Amplifying peptide hLF1-11, in the three therapeutic indications of acute renal failure, ulcerative colitis and hospital-acquired infections.

AM-Pharma recently announced positive results in two Phase IIa studies with Alkaline Phosphatase in acute renal failure and ulcerative colitis, whilst Selective Immune Response Amplifier hLF1-11 was shown to be safe in Phase I trials and in a first trial against infections in bone marrow transplant patients.

CEO Bart Wuurman said, “It’s great that investors continue to support us in moving our clinical programmes forward.”

Gunnar Weikert, Chairman of Inventages, added, “The clinical progress and data shown so far by the company are very encouraging. This is one of the few companies that have three products in Phase II development and an experienced team in place to maximize their value.”

Bart Bergstein of Forbion Capital Partners agreed, saying, “Given the strong pipeline, the expectation of a liquidity event via an IPO or trade sale in the upcoming period is more realistic than ever.”